Back to top
more

Incyte (INCY)

(Delayed Data from NSDQ)

$87.57 USD

87.57
2,070,856

+0.26 (0.30%)

Updated Oct 17, 2025 04:00 PM ET

After-Market: $87.57 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.81%
2Buy17.98%
3Hold9.90%
4Sell5.43%
5Strong Sell2.74%
S&P50011.32%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (78 out of 243)

Industry: Medical - Biomedical and Genetics

Zacks News

Zacks Equity Research

Biotech Stock Roundup: REGN, VIR's COVID-19 Updates, KMPH's Drug Approval & More

The biotech sector was in focus last week with regulatory and pipeline updates from quite a few companies like Regeneron (REGN), Vir (VIR) and KemPharm, Inc. (KMPH).

Zacks Equity Research

Acceleron (XLRN) Q4 Loss Wider Than Expected, Revenues Beat

Acceleron (XLRN) reports a wider loss in the fourth quarter of 2020 on higher costs and lower revenues.

Zacks Equity Research

The Zacks Analyst Blog Highlights: Regeneron Pharmaceuticals, Incyte, Nektar Therapeutics, Immunome and Otonomy

The Zacks Analyst Blog Highlights: Regeneron Pharmaceuticals, Incyte, Nektar Therapeutics, Immunome and Otonomy

Zacks Equity Research

Biotech Stock Roundup: Regulatory Updates From REGN, INCY, & Other Updates

The biotech sector was in focus last week with regulatory and pipeline updates from quite a few companies like Regeneron (REGN), Incyte (INCY) and Nektar (NKTR).

Zacks Equity Research

The Zacks Analyst Blog Highlights: Biogen, Gilead Sciences, Regeneron Pharma, Bristol-Myers Squibb and Incyte

The Zacks Analyst Blog Highlights: Biogen, Gilead Sciences, Regeneron Pharma, Bristol-Myers Squibb and Incyte

Zacks Equity Research

Biotech Stock Roundup: Q4 Results of BMY, REGN, BIIB & Other Regulatory Updates

Earnings of leading biotechs like Biogen (BIIB), Gilead (GILD) and Regeneron (REGN) dominate last week's headlines in the biotech sector.

Zacks Equity Research

Bristol Myers (BMY) Gets European Commission Nod for Inrebic

The European Commission approves Bristol Myers' (BMY) Inrebic for the treatment of adult patients with newly diagnosed and previously treated myelofibrosis.

Zacks Equity Research

Incyte (INCY) Q4 Earnings and Revenues Top Estimates

Incyte (INCY) delivered earnings and revenue surprises of 13.41% and 17.87%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Incyte (INCY) to Report Q4 Earnings: What's in the Cards?

Investors are likely to focus on pipeline updates besides top and bottom-line numbers when Incyte (INCY) reports fourth-quarter 2020 results.

Zacks Equity Research

Tiziana (TLSA) Posts Positive Data on Nasal COVID-19 Antibody

Tiziana (TLSA) reports positive data from a study investigating its anti-CD3 human monoclonal antibody, foralumab (nasally administered) for treating COVID-19 patients in Brazil. Shares up.

Zacks Equity Research

Incyte (INCY) Gets Positive CHMP Opinion for Pemigatinib

Incyte's (INCY) pemigatinib gets positive CHMP opinion by the EMA for the treatment of unresectable locally advanced or metastatic cholangiocarcinoma with a FGFR2 fusion.

Zacks Equity Research

Eli Lilly (LLY) Q4 Earnings Top, COVID-19 Antibody Boosts Sales

Lilly (LLY) beats fourth-quarter estimates for both earnings and sales. Stock up in pre-market trading.

Zacks Equity Research

Novartis (NVS) Misses on Q4 Earnings, Issues Grim 2021 Outlook

Novartis (NVS) reports dismal fourth-quarter results as the pandemic affected sales. The outlook for 2021 also indicates challenges ahead.

Zacks Equity Research

Lilly's (LLY) Bamlanivimab Combo Lowers COVID-19 Hospitalization

Eli Lilly's (LLY) combination of its COVID-19 antibodies bamlanivimab (LY-CoV555) plus etesevimab (LY-CoV016) reduces COVID-19-related hospitalizations and deaths by 70%.

Zacks Equity Research

Will Eli Lilly (LLY) Beat Estimates This Earnings Season?

Higher demand for its growth drugs is likely to have offset generic competition for several other drugs to boost Lilly's (LLY) fourth-quarter sales.

Zacks Equity Research

Incyte's (INCY) BLA for Cancer Drug Accepted for Priority Review

Incyte's (INCY) application for pipeline candidate, retifanlimab, for adult patients with locally advanced or metastatic squamous cell carcinoma of the anal canal (SCAC) gets Priority Review.

Zacks Equity Research

Lilly's (LLY) Bamlanivimab Lowers COVID-19 Risk in Nursing Homes

Eli Lilly's (LLY) COVID-19 antibody drug bamlanivimab (LY-CoV555) reduces risk of contracting symptomatic COVID-19 infection by 80% at nursing homes in the United States.

Zacks Equity Research

Alexion (ALXN) to Pause Enrollment in COVID-19 Study on Ultomiris

Alexion (ALXN) decides to stop further enrollment in the late-stage study of Ultomiris in adults with severe COVID-19 requiring mechanical ventilation due to lack of efficacy.

Zacks Equity Research

Merus (MRUS) Stock Up on FDA's Fast Track Tag for Zenocutuzumab

The FDA bestows a Fast Track status to Merus' (MRUS) lead pipeline candidate, Zenocutuzumab, for treating metastatic solid tumors harboring NRG1 gene fusions. Shares rise.

Zacks Equity Research

Xencor (XNCR) Inks Deal for Novel Antibody Therapies in Cancer

Xencor (XNCR) signs a strategic research collaboration deal with MD Anderson Cancer Center to develop and commercialize T Cell-engaging bispecific antibodies for treating cancer.

Zacks Equity Research

Biotech Stock Roundup: MRNA's COVID-19 Vaccine Updates & Other Pipeline Updates

The biotech sector was in focus last week with COVID-19 vaccine study updates from Moderna (MRNA) and other regulatory updates.

Zacks Equity Research

RedHill (RDHL) COVID-19 Drug Shows Promise in Mid-Stage Study

RedHill's (RDHL) opaganib achieves greater improvement in reducing oxygen requirement compared to placebo in a phase II study evaluating it in patients hospitalized with COVID-19 pneumonia.

Zacks Equity Research

Incyte (INCY) Partners With Cellenkos for Myelofibrosis Treatment

Incyte (INCY) enters into a collaboration with Cellenkos to evaluate the combination of Jakafi and CK0804 in patients with myelofibrosis.

Zacks Equity Research

Regeneron (REGN) Releases Initial Data on Cocktail for COVID-19

Regeneron (REGN) reports positive initial data on its antibody cocktail, casirivimab and imdevimab, in hospitalized COVID-19 patients requiring low-flow oxygen.

Zacks Equity Research

Merck (MRK) to Supply Coronavirus Treatment to U.S. Government

Merck (MRK) inks an agreement with the Government of United States for supplying MK-7110, being developed for treating patients with serious COVID-19, if approved.